Excellent
Mostly Aligned
Patient Risk:
Low
Summary
Most claims align with the provided VIAGRA label excerpts, especially indication, sildenafil identity, dosing range/timing, nitrate contraindication and interaction effects, alpha-blocker precautions, PDE5 safety counseling for vision/hearing, and general PDE5-inhibitor combination guidance (where applicable). A few claims are partially mismatched/overconfident versus the provided wording (e.g., “major safety issue” framing; “other PDE5 inhibitors differ” not specified in excerpts).
Category Scores
Accurate Statements
“Sildenafil is the active ingredient in “generic Viagra.””
Label lists VIAGRA active ingredient as sildenafil citrate; section 3/label excerpts indicate sildenafil citrate equivalent to 25/50/100 mg.
“Generic sildenafil products are intended to work the same way for erectile dysfunction.”
Label indicates VIAGRA (sildenafil) is indicated for treatment of erectile dysfunction and describes mechanism via PDE5 inhibition (section 1, 12.1).
“The key detail to check for a specific generic is the drug name on the label: sildenafil (not just “Viagra”).”
Label identifies sildenafil citrate as the active ingredient and provides dosage forms/strengths of sildenafil (sections 3 and 2).
“Generic sildenafil is commonly sold in tablet strengths of 25 mg, 50 mg, and 100 mg for erectile dysfunction.”
Label: tablets contain sildenafil citrate equivalent to 25 mg, 50 mg, or 100 mg (section 3).
“The right starting dose of generic sildenafil depends on factors like other medicines, age, and tolerability.”
Label: recommended starting/adjusted doses based on effectiveness/toleration; adjustments for alpha-blockers, strong CYP3A4 inhibitors, ritonavir, and special populations including >65 years, hepatic impairment, severe renal impairment (sections 2.1, 2.3, 2.4, 2.5).
“Erectile-dysfunction medications are often counterfeited.”
“Sildenafil interaction safety is a major safety issue.”
Label emphasizes contraindication/precautions for nitrates and alpha-blockers and provides interaction-specific warnings (sections 4.1, 5.5, 7.1, 7.2).
“The most important drug interaction for sildenafil is with nitrates used for chest pain/angina.”
Label: contraindicated with nitrates/NO donors (sections 4.1 and 7.1).
“Combining nitrates with sildenafil can dangerously lower blood pressure.”
Label: sildenafil shown to potentiate hypotensive effects of nitrates; administration with nitrates is contraindicated (sections 4.1 and 7.1; plus pharmacodynamic blood pressure decreases 12.2).
“Clinicians may screen for other blood-pressure medicines and alpha-blockers when considering sildenafil.”
Label advises caution with alpha-blockers and notes potential additive blood pressure-lowering leading to symptomatic hypotension (section 5.5 and 7.2).
“Sildenafil is usually taken as needed before sex.”
Label: recommended dose is 50 mg taken as needed approximately 1 hour before sexual activity; can be taken 30 minutes to 4 hours before (section 2.1).
“The effects of sildenafil can last into the hours after dosing.”
“Heavy or fatty meals can delay the onset of sildenafil.”
“Some erectile dysfunction products are not sildenafil, such as tadalafil (Cialis).”
“Other erectile dysfunction products may be PDE5 inhibitors besides sildenafil.”
Label warns against using combinations of VIAGRA with other PDE5 inhibitors (section 5.7), implying other PDE5 inhibitors exist as a class.
“Tadalafil and other PDE5 inhibitors differ in onset and duration compared with sildenafil.”
Unsupported Statements
“Erectile-dysfunction medications are often counterfeited.”
No counterfeit/forgery information appears in the provided label excerpts.
“The effects of sildenafil can last into the hours after dosing.”
The provided excerpts do not describe duration of effect after dosing.
“Heavy or fatty meals can delay the onset of sildenafil.”
The provided excerpts only state VIAGRA may be taken with or without food; they do not mention heavy/fatty meal effects on onset.
“Some erectile dysfunction products are not sildenafil, such as tadalafil (Cialis).”
The provided excerpts do not name tadalafil/Cialis or non-sildenafil ED products.
“Tadalafil and other PDE5 inhibitors differ in onset and duration compared with sildenafil.”
The provided excerpts do not provide comparative onset/duration information between PDE5 inhibitors.
Contradictions
Low
AI Statement
“Heavy or fatty meals can delay the onset of sildenafil.”
Label Reference
Label says VIAGRA may be taken with or without food (section 2.2).
Important Omissions
Nitrate contraindication and alpha-blocker precautions are discussed, but the specific instruction that VIAGRA with nitrates/NO donors is contraindicated (not merely “dangerous”) is not stated in several claims’ wording (e.g., no explicit contraindication phrasing).
Importance:
Moderate
Label-specific contraindication with GC stimulator (riociguat) and hypersensitivity contraindication are not mentioned in the provided AI claims.
Importance:
Moderate
Label provides counseling to stop PDE5 inhibitors and seek prompt medical attention for sudden vision loss (NAION) and sudden hearing loss; these are not included in the provided claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Most safety-critical interaction/cardiovascular contraindication themes (nitrates/NO donors contraindication; blood pressure-lowering with alpha-blockers) are aligned with label excerpts. However, several claims are unsupported (duration-of-effect, food/fatty meal onset, counterfeit prevalence) and one claim may conflict with the provided label excerpt that VIAGRA may be taken with or without food.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Some claims are unsupported by the provided VIAGRA label excerpts (counterfeit prevalence; duration of effect; fatty meal effect; tadalafil comparisons). One food-related claim is potentially inconsistent with the excerpt stating VIAGRA may be taken with or without food.
Suggested Improvement
Remove or qualify unsupported claims not present in the provided label excerpts (counterfeiting, duration after dosing, fatty-meal onset delay, tadalafil/non-sildenafil comparisons). Where safety is discussed, use label-consistent phrasing for contraindications/precautions (e.g., nitrates/NO donors are contraindicated; include riociguat and hypersensitivity contraindications if relevant; include label counseling for sudden vision/hearing loss).